Alivus Life Sciences Ltd share price logo

Alivus Life Sciences Ltd

NSE: ALIVUS

BSE: 543322

Small Cap

Pharma Sector

₹1164.10

-4.30

(-0.37%)

as on

bell
The current prices are delayed by 15 mins, login to check live prices.

Tech Chart

Alivus Life Sciences Stock Performance

as on July 16, 2026 at 9:31 pm IST

  • Day's Low

    Day's High

    ₹1,150.20
    ₹1,192.00
    downward going graph

    1.19%

    Downside

    2.40%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    ₹819.00
    ₹1,193.90
    downward going graph

    29.65%

    Downside

    2.56%

    Upside

    downward going graph

Alivus Life Sciences share price movements today

Previous Close
₹1,168.40
Open
₹1,170.00
Volume
6.27L
Upper Circuit
₹1,402.00
Lower Circuit
₹934.80
Day's Low - High
₹1,150.20 - ₹1,192.00
52 Week Low - High
₹819.00 - ₹1,193.90

Alivus Life Sciences Historical Returns

1 Month Return
+ 11.83 %
3 Month Return
+ 9.07 %
1 Year Return
+ 9.59 %
3 Year Return
+ 97.3 %
5 Year Return
+ 56.1 %

Alivus Life Sciences Fundamentals

as on July 16, 2026 at 4:01 pm IST

Market Cap

₹14,340.88 Cr

Return on Equity (ROE)

18.86

PE Ratio (TTM)

25.41

Return on capital employed (ROCE)

24.97

Industry PE ratio

54.32

Beta (LTM)

0.58

P/B Ratio

4.7

Dividend Yield

0

PEG Ratio

3.99

Quarterly Earnings Growth YOY

14.65

EPS (TTM)

0

Book Value

0

Alivus Life Sciences Stock Valuation

as on July 16, 2026 at 4:01 pm IST

Alivus Life Sciences in the last 5 years

  • Overview

  • Trends

Lowest (10.31x)

March 31, 2023

Today (25.41x)

July 15, 2026

Industry (54.32x)

July 15, 2026

Highest (35.94x)

September 16, 2024

LowHigh

Today’s Price to Earnings Ratio: 25.41x

Alivus Life Sciences Technical Analysis

Track how Alivus Life Sciences technical analysis has moved over time to understand its trends.

1 min
5 min
15 min
30 min
1 day
1 week
1 month

Technicals Summary

Bearish

Neutral

Bullish

Bullish

Moving Averages

Bearish

Neutral

Bullish

Bullish

Oscillators

Bearish

Neutral

Bullish

Neutral

Overall

Bearish4
Bullish9
Neutral2

Oscillators

Name

Value

Action

MACD level (12,26)
0.16
Bearish
CCI (20)
666.67
Bearish
RSI (14)
60.12
Neutral
Momentum (10)
0.4
Bullish
ADI (14)
26.4
Bullish
Ultimate Oscillator (7,14,28)
34.06
Neutral

Moving Averages

Name

Value

Action

SMA (20)
1164.11
Bullish
EMA (20)
1164.1
Bullish
VWMA (20)
1164.13
Bullish
SMA (50)
1164.16
Bullish
EMA (50)
1163.65
Bullish
SMA (200)
1172.9
Bearish
EMA (200)
1169.62
Bearish
KAMA (200)
1163.28
Bullish
DEMA (200)
1163.17
Bullish

Alivus Life Sciences Ltd vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Alivus Life Sciences with its industry peers.

Company
Analyst View
Market Cap(in ₹ Cr)
5 Year CAGRDebt to Asset Ratio
Net Profit(in ₹ Cr)
Yearly Revenue(in ₹ Cr)
Alivus Life Sciences Ltd image
Alivus Life Sciences Ltd
BUY14,340.8811.22%0.004852,386
Sanofi India Ltd image
Sanofi India Ltd
BUY7,777.23-11.52%0.004132,013
Gennex Laboratories Ltd image
Gennex Laboratories Ltd
NA225.46-1.25%0.5818137
Gufic BioSciences Ltd image
Gufic BioSciences Ltd
NA3,977.2023.11%0.6969819
Nectar Lifescience Ltd image
Nectar Lifescience Ltd
NA210.97-14.67%0.69-1141,669
See all

Market expectation of Alivus Life Sciences Stock

Common consensus of the market based on various publicly available news, publications,brokerage expectation and market data

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Alivus Life Sciences Stock’s Investor Sentiment and Interest

Search interest for Alivus Life Sciences Ltd Stock has increased by 92% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:92% versus previous 30 day period

Alivus Life Sciences Ltd Quarterly Profit & Loss

Figures in Rupees Crores

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Sales
595.36
572.8
536.6
588.62
506.88
641.84
649.55
601.85
587.98
672.89
689.12
Other Income
5.37
1.69
3.13
5.49
8.53
10.46
10.09
8.99
14.72
13.93
22.78
Total Income
600.73
574.5
539.73
594.11
515.41
652.3
659.63
610.83
602.7
686.82
711.9
Expenses
428.28
400.25
395.15
429.13
372.52
451.54
451.11
429.54
408.81
467.27
474.59
Operating Profit
167.08
172.55
141.45
159.49
134.36
190.3
198.44
172.31
179.17
205.62
214.53
Operating Profit Margin %
28.06%
30.12%
26.36%
27.1%
26.51%
29.65%
30.55%
28.63%
30.47%
30.56%
31.13%
Profit Before Interest, Tax and Depreciation
172.45
174.25
144.58
164.98
142.89
200.76
208.52
181.3
193.89
219.54
237.31
Interest
0.4
0.39
0.36
0.35
0.34
0.46
1.26
1.25
1.32
1.49
1.31
Depreciation
13.13
13.18
14.53
14.39
15.09
15.16
15.97
17.06
18.44
19.66
20.2
Profit Before Tax
158.92
160.68
129.69
150.24
127.46
185.14
191.29
162.99
174.13
198.39
215.8
Tax Paid
40.19
41.92
31.74
38.76
32.14
48.19
49.43
41.45
44.11
48.13
53.14
Profit After Tax
118.74
118.77
97.94
111.48
95.32
136.96
141.87
121.54
130.03
150.26
162.66
Total Net profit including share of profit / Loss from associate company
118.74
118.77
97.94
111.48
95.32
136.96
141.87
121.54
130.03
150.26
162.66
EPS
9.69
9.69
7.99
9.1
7.78
11.18
11.57
9.91
10.6
12.25
13.23
Actual EPS
9.69
9.69
7.99
9.1
7.78
11.18
11.57
9.91
10.6
12.25
13.23
Adjusted EPS
9.69
9.69
7.99
9.1
7.78
11.18
11.57
9.91
10.6
12.25
13.23
Diluted EPS
9.69
9.67
7.97
9.08
7.75
11.14
11.55
9.88
10.58
12.22
13.22

Alivus Life Sciences Ltd Annual Profit & Loss

Figures in Rupees Crores

Mar 2019
Mar 2020
Mar 2021
Sales
886.42
1,537.31
1,885.17
Other Income
0.44
11.99
0.81
Total Income
886.87
1,549.3
1,885.98
Expenses
638.7
1,065.35
1,294.09
Operating Profit
247.72
471.96
591.08
Operating Profit Margin %
27.95%
30.7%
31.35%
Profit Before Interest, Tax and Depreciation
248.16
483.95
591.89
Interest
0.61
33.52
87.55
Depreciation
19.26
29.37
33.39
Profit Before Tax
228.29
421.06
470.95
Tax Paid
32.71
107.97
119.37
Profit After Tax
195.59
313.1
351.58
Total Net profit including share of profit / Loss from associate company
195.59
313.1
351.58
EPS
24.64
29.04
32.61
Actual EPS
24.64
29.04
32.61
Adjusted EPS
0.45
0.53
2.96
Diluted EPS
24.64
29.04
32.61

Alivus Life Sciences Ltd Cash Flow

Figures in Rupees Crores

Mar 2018
Mar 2019
Mar 2020
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Net Cash from Operating Activities
-0.48
10.35
195.01
388.11
597.59
306.01
413.52
391.52
Cash Flow from Investing Activities
-
-8.84
-50.52
-68.74
-122.22
-146.75
-116.48
-615.65
Cash Flow from Financing Activities
0.49
0.53
-136.55
-213.78
-78.8
-387.6
-279.45
-6.23
Net Cash Flow
0.01
2.05
7.94
105.6
396.56
-228.33
17.59
-230.35

Alivus Life Sciences Stock Shareholding Pattern

Numbers in percentages

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Promoters
82.85%
82.85%
82.85%
82.85%
75%
75%
74.99%
74.94%
74.91%
74.91%
74.87%
74.87%
DII
0.64%
0.59%
1.4%
1.57%
4.16%
4.86%
5.19%
5.61%
5.47%
7.12%
7.28%
7.18%
FII
4.38%
0%
5.01%
4.82%
7.85%
6.74%
6.57%
6.42%
6.84%
5.09%
5.29%
5.54%
Public
12.12%
11.84%
10.73%
10.76%
12.98%
13.4%
13.25%
13.03%
12.78%
12.88%
12.56%
12.41%
Total Outstanding Shares
12,25,27,172
12,25,27,172
12,25,27,172
12,25,27,172
12,25,28,672
12,25,32,862
12,25,37,052
12,26,29,148
12,26,81,348
12,26,81,348
12,27,36,348
12,27,39,448
Total Shareholders
1,98,764
1,85,531
1,56,183
1,49,396
1,43,960
1,46,840
1,41,977
1,38,500
1,35,643
1,32,748
1,27,969
1,25,559

Mutual Funds that own Alivus Life Sciences Stock

Check out the Mutual Funds with significant holdings in Alivus Life Sciences.

Alivus Life Sciences Corporate Actions

View detailed summary of the earnings and dividend history of Alivus Life Sciences.

  • Alivus Life Sciences Ltd Earnings Results

    Alivus Life Sciences Ltd’s net profit jumped 14.65% since last year same period to ₹162.66Cr in the Q4 2025-2026. On a quarterly growth basis, Alivus Life Sciences Ltd has generated 8.25% jump in its net profits since last 3-months.

    Read More about Earnings Results

  • Alivus Life Sciences Ltd Dividends May,2025

    In the quarter ending March 2025, Alivus Life Sciences Ltd has declared dividend of ₹5.00 per share on 15 May 2025 - translating a dividend yield of 0.43%.

    Read More about Dividends

Indices Featuring Alivus Life Sciences Stock

Check stock indices that include Alivus Life Sciences.

BSE Healthcare

₹50,418.51

-42.27 (▲0.08%)

Insights on Alivus Life Sciences Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    FII Holding Up

    img

    Foreign Institutions have increased holdings from 5.09% to 5.29% in Mar 2026 quarter

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 1 month, ALIVUS stock has moved up by 11.8%

  • imgPOSITIVE IMPACT

    MF Holding Up

    img

    Mutual Funds have increased holdings from 5.44% to 5.63% in Mar 2026 quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Torrent Pharmaceuticals Ltd has given 45.0% return, outperforming this stock by 35.5%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Torrent Pharmaceuticals Ltd has given 158.3% return, outperforming this stock by 61.0%

  • imgNEGATIVE IMPACT

    Promoter Holding Down

    img

    Promoters have decreased holdings from 74.91% to 74.87% in Mar 2026 quarter

  • imgNEGATIVE IMPACT

    Retail Holding Down

    img

    Retail Investor have decreased holdings from 12.88% to 12.56% in Mar 2026 quarter

About Alivus Life Sciences Ltd

Glenmark Life Sciences Private Limited (formerly Zorg Laboratories Private Limited) was incorporated as a private limited company on 23 June 2011. It was acquired by Glenmark Pharmaceuticals Limited in July 2018, and was converted to a public company in August 2018. Operating as a wholly-owned subsidiary of Glenmark Pharmaceuticals, the company is engaged in the development, manufacture, and marketing of active pharmaceutical ingredients (APIs). The company has Research and Development (R&D) facilities in Mahape, Ankleshwar, and Dahej, while its manufacturing facilities are located in Ankleshwar, Dahej, Mohol, and Kurkumbh. On 13 August 2018, Glenmark Life Sciences allotted 4,500,090 equity shares of Rs. 10 each upon conversion of a loan given to the Director, and 15,000,000 shares to its parent company Glenmark Pharmaceuticals under preferential allotment. The company recently concluded its IPO, of a total of 21,022,222 equity shares, raising Rs. 15136 million. All of the outstanding purchase consideration was repaid from the proceeds of the IPO, and the company’s equity shares are now listed on both the BSE and NSE.

Revenue: ₹689.12Cr as on March 2026 (Q4 FY26)
Net Profit: ₹162.66Cr as on March 2026 (Q4 FY26)
Listing date: 06 Aug, 2021
Chairperson Name: Glenn Saldanha
OrganisationAlivus Life Sciences Ltd
IndustryPharmaceuticals
CEOGlenn Saldanha
E-voting on sharesClick here to vote

FAQs

What is Alivus Life Sciences share price today?

Alivus Life Sciences share price today stands at ₹1164.1 as on at the close of the market. Alivus Life Sciences share today touched a day high of ₹1192 and a low of ₹1150.2.

What is the 52 week high and 52 week low range for Alivus Life Sciences share?

Alivus Life Sciences touched a 52 week high of ₹1193.9 and a 52 week low of ₹819. Alivus Life Sciences share price today i.e. is closed at ₹1164.1, which is -2.50% down from its 52 week high and 42.14% up from its 52 week low.

What is Alivus Life Sciences's market capitalisation today?

Alivus Life Sciences market capitalisation is ₹14,340.88 Cr as on .

How to buy Alivus Life Sciences shares?

To buy Alivus Life Sciences shares, you need to follow these steps:

  • Open a Demat account and Trading account on INDmoney
  • Fund your Trading account
  • Search for ALIVUS or Alivus Life Sciences Ltd on the INDmoney app to check live prices of the stock
  • Click on Buy or SIP to place an order to invest in Alivus Life Sciences shares. You can invest by selecting the number of shares or set up a fixed SIP to invest every month or week.

What is Alivus Life Sciences trading volume today?

Alivus Life Sciences trading volume is 6.27L as on . This means that 6.27L shares of Alivus Life Sciences were bought and sold on the stock market during today's trading session.